Everolimus-induced interstitial lung disease in patient with metastatic renal cell carcinoma – case report and literature review Case report
Article Sidebar
Published:
May 15, 2015
Keywords:
everolimus, interstitial lung disease, metastatic renal cell carcinoma
Main Article Content
Abstract
We present a case of a 70-year-old man with metastatic renal cell carcinoma treated with second-line everolimus after rapid progression on first-line tyrosine kinase inhibitor, in whom a side effect of the therapy occurred in the form of a drug-induced interstitial lung disease. We also provide a review of the literature concerning opinions on incidence, clinical picture, consequences and management of the complication discussed.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Article Details
How to Cite
1.
Buraczewska A, Kardas J. Everolimus-induced interstitial lung disease in patient with metastatic renal cell carcinoma – case report and literature review. OncoReview [Internet]. 2015May15 [cited 2024Apr.28];5(3(19):117-21. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/398
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Summary of Product Characteristics AFINITOR. Online: www.ema.europa.eu/docs/pl_PL/document.../WC500022814.pdf.
2. Porta C, Osanto S, Ravaud A et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011; 47(9): 1287-98.
3. Saito Y, Kunugi S, Suzuki Y et al. Granuloma-forming interstitial pneumonia occurring one year after the start of everolimus therapy. Intern Med 2013; 52(2): 263-7.
4. Akata K, Yatera K, Ishimoto H et al. Two cases of everolimus-associated interstitial pneumonia in patients with renal cell carcinoma. Intern Med 2011; 50(24): 3013-7.
5. Baas MC, Struijk GH, Moes DJ et al. Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients. Transpl Int 2014; 27(5): 428-36.
6. Vandewiele B, Vandecasteele SJ, Vanwalleghem L, De Vriese AS. Diffuse alveolar hemorrhage induced by everolimus. Chest 2010; 137(2): 456-9.
7. Duran I, Siu LL, Oza AM et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006; 42: 1875-80.
8. Iacovelli R, Palazzo A, Mezi S et al. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol 2012; 51(7): 873-9.
9. Nozawa M, Nonomura N, Ueda T et al. Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice. Jpn J Clin Oncol 2013; 43(11): 1132-8.
10. Park K, Lee JL, Ahn JH et al. Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma following treatment failure with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor. Cancer Res Treat 2014; 46(4): 339-47.
11. White DA, Camus P, Endo M et al.: Non-infectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182: 396-403.
12. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372(9637): 449-56.
13. Park K, Kim HJ, Lee JL et al. Changes in the diffusion capacity for carbon monoxide and the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus. Anticancer Res 2014; 34(10): 5723-8.
14. Eisen T, Sternberg CN, Robert C et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 2012; 104(2): 93-113.
15. Grünwald V, Weikert S, Pavel ME et al. Practical management of everolimus-related toxicities in patients with advanced solid tumors. Onkologie 2013; 36(5): 295-302.
16. Méndez-Vidal MJ, Martínez Ortega E, Montesa Pino A et al. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Cancer Metastasis Rev 2012; 31 Suppl 1: S19-27.
17. Willemsen AE, De Vos FY, Jansen A et al. Diagnostic challenges of respiratory adverse events during everolimus treatment. Target Oncol 2014; 9(3): 287-91.
18. Saito Y, Nagayama M, Miura Y et al. A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma. Jpn J Clin Oncol 2013; 43(5): 559-62.
19. Kubo K, Azuma A, Kanazawa M et al: Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Resp Investigation 2013; 51: 260-277.
20. Dabydeen DA, Jagannathan JP, Ramaiya N et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 2012; 48(10): 1519-24.
21. Atkinson BJ, Cauley DH, Ng C et al. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int 2014; 113(3): 376-82.
2. Porta C, Osanto S, Ravaud A et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011; 47(9): 1287-98.
3. Saito Y, Kunugi S, Suzuki Y et al. Granuloma-forming interstitial pneumonia occurring one year after the start of everolimus therapy. Intern Med 2013; 52(2): 263-7.
4. Akata K, Yatera K, Ishimoto H et al. Two cases of everolimus-associated interstitial pneumonia in patients with renal cell carcinoma. Intern Med 2011; 50(24): 3013-7.
5. Baas MC, Struijk GH, Moes DJ et al. Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients. Transpl Int 2014; 27(5): 428-36.
6. Vandewiele B, Vandecasteele SJ, Vanwalleghem L, De Vriese AS. Diffuse alveolar hemorrhage induced by everolimus. Chest 2010; 137(2): 456-9.
7. Duran I, Siu LL, Oza AM et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006; 42: 1875-80.
8. Iacovelli R, Palazzo A, Mezi S et al. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol 2012; 51(7): 873-9.
9. Nozawa M, Nonomura N, Ueda T et al. Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice. Jpn J Clin Oncol 2013; 43(11): 1132-8.
10. Park K, Lee JL, Ahn JH et al. Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma following treatment failure with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor. Cancer Res Treat 2014; 46(4): 339-47.
11. White DA, Camus P, Endo M et al.: Non-infectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182: 396-403.
12. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372(9637): 449-56.
13. Park K, Kim HJ, Lee JL et al. Changes in the diffusion capacity for carbon monoxide and the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus. Anticancer Res 2014; 34(10): 5723-8.
14. Eisen T, Sternberg CN, Robert C et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 2012; 104(2): 93-113.
15. Grünwald V, Weikert S, Pavel ME et al. Practical management of everolimus-related toxicities in patients with advanced solid tumors. Onkologie 2013; 36(5): 295-302.
16. Méndez-Vidal MJ, Martínez Ortega E, Montesa Pino A et al. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Cancer Metastasis Rev 2012; 31 Suppl 1: S19-27.
17. Willemsen AE, De Vos FY, Jansen A et al. Diagnostic challenges of respiratory adverse events during everolimus treatment. Target Oncol 2014; 9(3): 287-91.
18. Saito Y, Nagayama M, Miura Y et al. A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma. Jpn J Clin Oncol 2013; 43(5): 559-62.
19. Kubo K, Azuma A, Kanazawa M et al: Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Resp Investigation 2013; 51: 260-277.
20. Dabydeen DA, Jagannathan JP, Ramaiya N et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 2012; 48(10): 1519-24.
21. Atkinson BJ, Cauley DH, Ng C et al. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int 2014; 113(3): 376-82.